XTX Topco Ltd Takes $64,000 Position in Biodesix, Inc. (NASDAQ:BDSX)

XTX Topco Ltd bought a new stake in Biodesix, Inc. (NASDAQ:BDSX) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 103,153 shares of the company’s stock, valued at approximately $64,000. XTX Topco Ltd owned 0.07% of Biodesix as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Balyasny Asset Management L.P. acquired a new stake in shares of Biodesix in the 4th quarter valued at $29,000. Boothbay Fund Management LLC acquired a new stake in shares of Biodesix in the 4th quarter valued at $52,000. MYDA Advisors LLC acquired a new stake in shares of Biodesix in the 4th quarter valued at $76,000. Cubist Systematic Strategies LLC grew its stake in shares of Biodesix by 385.9% during the fourth quarter. Cubist Systematic Strategies LLC now owns 51,024 shares of the company’s stock worth $78,000 after purchasing an additional 40,524 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of Biodesix during the fourth quarter worth $119,000. 20.96% of the stock is owned by institutional investors and hedge funds.

Biodesix Stock Down 0.2%

NASDAQ:BDSX opened at $0.40 on Friday. Biodesix, Inc. has a 1 year low of $0.17 and a 1 year high of $2.04. The company has a current ratio of 2.14, a quick ratio of 2.22 and a debt-to-equity ratio of 41.11. The stock has a market cap of $58.11 million, a price-to-earnings ratio of -1.37 and a beta of 0.99. The stock has a 50-day moving average price of $0.33 and a two-hundred day moving average price of $0.53.

Biodesix (NASDAQ:BDSX) last posted its earnings results on Thursday, August 7th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Biodesix had a negative net margin of 53.66% and a negative return on equity of 269.67%. The business had revenue of $20.02 million during the quarter, compared to analyst estimates of $18.47 million. As a group, equities analysts expect that Biodesix, Inc. will post -0.35 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on BDSX. William Blair reaffirmed a “market perform” rating on shares of Biodesix in a research note on Wednesday, May 14th. Lake Street Capital decreased their price objective on Biodesix from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Wednesday, May 14th. Scotiabank decreased their price objective on Biodesix from $3.00 to $2.00 and set a “sector outperform” rating for the company in a research note on Wednesday, May 21st. Craig Hallum decreased their price objective on Biodesix from $3.00 to $1.50 and set a “buy” rating for the company in a research note on Wednesday, May 14th. Finally, Canaccord Genuity Group decreased their price objective on Biodesix from $2.50 to $1.50 and set a “buy” rating for the company in a research note on Wednesday, May 14th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1.75.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.